Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis treatment Taltz, improved arthritis symptoms and drove weight loss better than Tal... ...

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Eli Lilly and Company (NYSE: LLY) for $14.00 per share of common stock in an all-cash transaction (equal to an aggregate equity val ...

礼来公司（LLY）周四早盘下跌0.2%。该公司同意以全现金交易收购Ventyx Biosciences（VTYX），以 扩展其针对多种疾病慢性炎症的口服小分子疗法产品线。 礼来公司（LLY）周四早盘下跌0.2%。该公司同意以全现金交易收购Ventyx Biosciences（VTYX），以 扩展其针对多种疾病慢性炎症的口服小分子疗法产品线。 责任编辑：张俊 SF065 责任编辑：张俊 SF065 ...

Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Ventyx Biosciences, Inc. (NASDAQ: VTYX) to Eli Lilly and Company for $14.00 per share is fair to Ventyx shareholders. Halper Sadeh encourages Ventyx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Ventyx and it. ...

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth-quarter 2025 investor letter. The investment philosophy of the strategy is to invest in leading companies that are undervalued by the market in terms of their future growth potential. A copy of the letter can be downloaded here. Large-cap stocks continued their strength in the quarter, driven by strong earnings growth from mega-cap companies and enthusiasm over generative AI. The ClearBridg ...

BREAKING: Futures Fall, Defense Stocks Rebound Today's Spotlight MarketSurge New Year Sale Invest smarter in 2026 with our BEST deal—14 months of MarketSurge for $1,499 ($600 off). Free Investing Podcast Listen to IBD's podcast for new investing tips and trade ideas every week. Subscribe today! Get Market Insights on IBD Live Join IBD Live to watch and discuss the market action in real time with top market analysts. More News Partner Center Related news Aerospace Play Woodward Leads Select Group Of 8 Onto B ...

Core Insights - The stock market showed mixed performance with Dow Jones, S&P 500, and Nasdaq futures slightly declining early Thursday, following a generally lower trend on Wednesday [3] - Eli Lilly confirmed its plan to acquire Ventyx Biosciences for $1.2 billion, which is a significant move in the biotech sector [6] - Quantum computing stocks have started strong in 2026, indicating potential growth in this emerging industry [5][8] Company Highlights - Eli Lilly's acquisition of Ventyx Biosciences is a strategic move to enhance its portfolio, particularly in the biotech space [6] - The stock of Eli Lilly is highlighted as a key focus for investors, with two potential entry points identified amid the rumored buyout rally [6] - Other notable companies in focus include Google and Nvidia, which are also nearing buy points as part of a broader market analysis [6] Industry Trends - The biotech sector is showing resilience with companies like Eli Lilly and Ionis Pharmaceuticals performing well [3] - The aerospace industry is represented by companies like Woodward, which have been added to top stock lists, indicating growth potential [3][4] - The quantum computing sector is gaining traction, suggesting a promising outlook for investors in this field [5][8]

格隆汇1月8日｜礼来将以每股14美元的价格收购自身免疫药物开发商Ventyx Biosciences，交易价值达12 亿美元。Ventyx正在开发多种治疗药物，包括治疗克罗恩病和溃疡性结肠炎等炎症性肠病的口服疗法， 以及治疗免疫相关疾病、心脏代谢疾病和神经退行性疾病的药物。此外，该公司正在进行中期试验的一 种药物针对的是与肥胖有关的心血管疾病，有可能与礼来公司的代谢和免疫专营权形成互补。该交易预 计将于今年上半年完成。 ...

智通财经APP获悉，礼来(LLY.US)确认已同意以每股14美元的现金收购Ventyx Biosciences (VTYX.US)。 根据周三发布的一份声明，该交易的总股权价值约为 12 亿美元。该交易不附加任何融资条件，预计将 于今年上半年完成。美银证券担任礼来的独家财务顾问，杰富瑞担任Ventyx的首席财务顾问。 总部位于圣地亚哥的Ventyx专注于研发治疗克罗恩病和类风湿性关节炎等炎症性疾病的药物，礼来收购 该公司旨在拓展其在免疫学领域的业务。 与此同时，该公司正在寻求收购以扩充其产品线。2024年，该公司以32亿美元收购了Morphic Therapeutics，获得了一种用于治疗炎症性肠病的实验性药物。此外，该公司还斥资24亿美元收购了 Dice Therapeutics，后者是一家开发口服银屑病疗法的公司。 礼来公司表示，免疫学是其关键增长领域，该公司希望在糖尿病和肥胖症治疗领域取得巨大成功的基础 上，进一步拓展业务。这些成功吸引了投资者和患者的关注。该公司目前已销售多种治疗关节炎和银屑 病等炎症性疾病的药物，包括Taltz，但Taltz的关键专利保护将在未来几年内到期。 ...